Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - fampridine - sklerosi multipla - drogi oħra tas-sistema nervuża - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

genzyme europe b.v. - alemtuzumab - lewkimja, linfokitika, kronika, b-Ċellula - aġenti antineoplastiċi - mabcampath huwa indikat għall-kura ta 'pazjenti b'lewkimja limfoċitika kronika taċ-Ċellula b (bcll) li għalihom il-kemjoterapija kombinata ta' fludarabine mhijiex xierqa.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

noden pharma dac - aliskiren - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - antigens tal-wiċċ tal-virus tal-influwenza (emagglutinin u neuraminidase) ta 'razza a / vjet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaċċini - immunizzazzjoni attiva kontra s-sottotip h5n1 tal-virus influwenza a.. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm ltd - aliskiren, amlodipine - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - rasilamlo huwa indikat għat-trattament ta 'pressjoni għolja essenzjali f'pazjenti adulti li l-pressjoni tad-demm tagħhom mhix ikkontrollata b'mod adegwat b'aliskiren jew amlodipine użat waħdu.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaċċini - active immunisation against h5 subtype of influenza a virus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

seqirus s.r.l.  - antiġeni tal-wiċċ tal-virus ta 'l-influwenza, inattivati: a / vjet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaċċini ta 'l-influwenza - profilassi tal-influwenza f'sitwazzjoni pandemika ddikjarata uffiċjalment. il-vaċċin kontra l-influwenza pandemika għandu jintuża skond il-gwida uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influwenza, bniedem - vaċċini kontra l-influwenza, influwenza, ħaj attenwat - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. l-użu ta 'fluenz tetra għandu jkun ibbażat fuq rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - virus, ħaj attenwat, ħosba, virus, ħaj attenwat, gattone, virus, ħaj attenwat, rubella, virus, ħaj attenwat, varikella - chickenpox; rubella; measles; mumps; immunization - vaċċini - proquad huwa indikat għal tilqim simultanju kontra ħosba, gattone, rubella u varikella f'individwi minn 12-il xahar. proquad jista 'jingħata lill-individwi minn 9 xhur ta' età taħt ċirkostanzi speċjali (e. , li jikkonformaw mal-nazzjonali-iskedi tat-tilqim, tifqigħa is-sitwazzjonijiet, jew jivvjaġġaw lejn ir-reġjun bil-prevalenza għolja tal-ħosba.